Bioimmunate Technologies
Blood Filtering Technology for Autoimmune Diseases
StartupBioimmunate Technologies is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2014. Blood Filtering Technology for Autoimmune Diseases. The company has raised a total of $1.95M across 2 funding rounds, currently at the Seed stage. Bioimmunate Technologies was founded by Sigalit Carmel, MD, PhD. Key investors include Undisclosed Investor(s). The company has 1-10 employees. Core technologies: Biologicals, Cells.
With $1.95M in total funding, Bioimmunate Technologies is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B2C business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B2C
- Employees1-10
- HQJerusalem
- DistrictJerusalem District
- Last Round$1M
- Undisclosed Investor(s)
Sigalit Carmel, MD, PhDFounder & CEO
What does Bioimmunate Technologies do?
Bioimmunate is a medical device company that offers a precision blood filtering medical technology for select autoimmune diseases. The companys platform technology is initially focused on the treatment of patients with multiple sclerosis (MS). Brain damage from MS is caused by specific MS-related cells that migrate from the blood to the brain. Bioimmunate has developed unique biological filters anchored inside special particles that are able to recognize, capture, and remove these harmful cells from the patients blood before they reach the central nervous system. Bioimmunate is dedicated to improving the quality of life of patients with autoimmune diseases, seeking to provide safer, more cost-effective therapies without side effects. The companys main R&D lab is located at the BioGiv Center at the Hebrew University in Jerusalem.
How much funding has Bioimmunate Technologies raised?
Bioimmunate Technologies has raised $1.95M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Undisclosed Investor(s).
Who founded Bioimmunate Technologies?
Bioimmunate Technologies was founded in 2014 by Sigalit Carmel, MD, PhD (Founder & CEO).
What sector is Bioimmunate Technologies in?
Bioimmunate Technologies operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Providers.
Where is Bioimmunate Technologies located?
Bioimmunate Technologies is based in Professor Racah St 3, Jerusalem, Israel, Jerusalem District.